Cassava ends simufilam Alzheimer’s programme after second Phase III failure
Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show…
Central Nervous System
-
-
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate…
-
Tempero secures $70m to advance addiction treatment candidate
Tempero Bio has raised $70m in Series B financing to advance its lead candidate TMP-301 through two clinical trials for…
-
Augustine secures $85m to advance Charcot-Marie-Tooth candidate
Belgium-based biotech Augustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it…
-
Roche’s discontinued Alzheimer’s drug shows signs of preventing onset
Roche’s discontinued Alzheimer’s disease drug has shown signs that it could prevent onset of the disease. The Phase II/III Knight…
-
EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia
The European Commission (EC) has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic Rxulti (brexpiprazole) for schizophrenia in adolescents aged 13…
-
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
Tris Pharma has reported another Phase III win with its investigational pain therapy, cebranopadol, and it is now setting up…
-
Newleos secures $93.5m for neuropsychiatric treatments
Newleos Therapeutics has closed an oversubscribed Series A financing round, raising $93.5m to revolutionise neuropsychiatric disorder treatments with new medicines.…
-
SmartCella gains rights to advance cell therapy research for Parkinson’s
SmartCella has secured exclusive rights to advance research into cell replacement therapies for the treatment of Parkinson's disease (PD). The…
-
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’…
